FDA panel wants more data on Lilly's Solpura

An expert panel refused to back Eli Lilly's Solpura (liprotamase), a pancreatic enzyme for the treatment of cystic fibrosis. It's the first treatment of its kind with enzymes derived from microbiology rather than pig parts. Lilly acquired Solpura as part of its $380 million buyout of Alnara Pharmaceuticals. The panel recommended Lilly conduct further tests to confirm the drug's effectiveness. Report